Close this search box.

Public equity report: Acrivon refreshes balance sheet with $130M PIPE

ARTICLE | Finance

Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists

By Paul Bonanos, Director of Biopharma Intelligence

April 12, 2024 9:58 PM UTC

RA Capital Management backed Acrivon and Eliem in nine-digit PIPEs this week, while Century drew a $60 million private placement as it made an acquisition, and Nurix rode a data readout to an upsized follow-on.

Precision oncology company Acrivon Therapeutics Inc. (NASDAQ:ACRV) raised $130 million in a PIPE that will support continued advancement of small molecule Chk1/Chk2 inhibitor ACR-368 in a Phase II study that could be registrational. Acrivon also presented preclinical data at the American Association for Cancer Research (AACR) meeting showing that dual WEE1/PKMYT1 inhibitor ACR-2316 showed stronger potency and ex vivo anticancer activity than comparators in each of the WEE1 and PKMYT1 classes…